Skip to main content

Table 5 The mean change and the cost of the change

From: Clinical and economic impact of a one-year treatment with omalizumab in patients with severe allergic asthma within a drug programme in Poland

The mean change at week 52 of OMB treatment

The cost per unit change (EUR)

OCS dose

−7.72941 (mg)

−2067.3

AQLQ scoring

1.856471 (points)

- 8607.3

ACQ scoring

−1.44941 (points)

−11,024.6

Number of physician office visitsa

−3.10588

−5144.8

Number of hospitalizationsa

−1.27059

- 12,576.2

Total number of the physician office visits and hospitalizationsa

−4.37647

− 3651.2

  1. a only associated with asthma exacerbations